Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,702.00
Bid: 10,678.00
Ask: 10,682.00
Change: 48.00 (0.45%)
Spread: 4.00 (0.037%)
Open: 10,694.00
High: 10,736.00
Low: 10,596.00
Prev. Close: 10,654.00

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Date   Source Headline
24th Feb 202311:00 amRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSAstraZeneca enters agreement with KYM for CMG901
22nd Feb 20237:10 amRNSFiling of Form 20-F with SEC
21st Feb 202311:00 amRNSAnnual Financial Report
13th Feb 20232:01 pmRNSDirector/PDMR Shareholding
13th Feb 20232:00 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSFinal Results
1st Feb 20233:00 pmRNSTotal Voting Rights
26th Jan 20236:15 pmRNSUpdate on Evusheld US EUA
16th Jan 20237:00 amRNSAcquisition of Neogene Therapeutics completed
11th Jan 20231:00 pmRNSAirsupra (PT027) approved in US for asthma
9th Jan 20237:00 amRNSAstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 20233:00 pmRNSTotal Voting Rights
30th Dec 202211:00 amRNSDirector/PDMR Shareholding
28th Dec 20227:05 amRNSCalquence Japan approval for treatment-naïve CLL
28th Dec 20227:00 amRNSImfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 20227:05 amRNSLynparza approved in EU for prostate cancer
21st Dec 20227:00 amRNSImfinzi approved in EU for biliary tract cancer
19th Dec 20227:20 amRNSEnhertu recommended for EU approval in HER2-low BC
19th Dec 20227:15 amRNSEnhertu approved in EU for gastric cancer
19th Dec 20227:10 amRNSImfinzi + Imjudo recommended for approvals in EU
19th Dec 20227:05 amRNSUpdate on Imfinzi PEARL trial
19th Dec 20227:00 amRNSForxiga CHMP opinion for symptomatic chronic HF
15th Dec 20227:00 amRNSUpdate on US review of Lynparza PROpel sNDA
8th Dec 20221:30 pmRNSCapivasertib PFS in HR-positive breast cancer
1st Dec 20223:00 pmRNSBlock listing Interim Review
1st Dec 20223:00 pmRNSTotal Voting Rights
30th Nov 20227:05 amRNSAstraZeneca announces sale of West Chester site
29th Nov 20227:00 amRNSAstraZeneca to acquire Neogene Therapeutics
23rd Nov 20223:30 pmRNSDirector/PDMR Shareholding
14th Nov 20227:10 amRNSEnhertu recommended for EU approval in gastric
14th Nov 20227:05 amRNSImfinzi recommended for approval in the EU for BTC
14th Nov 20227:00 amRNSLynparza combo recommended in the EU for mCRPC
11th Nov 20227:00 amRNSImfinzi + Imjudo approved in US for lung cancer
10th Nov 20227:00 amRNSYTD and Q3 2022 Results
9th Nov 20227:00 amRNSFDA Advisory Committee recommends PT027 in asthma
4th Nov 20227:00 amRNSBeyfortus (nirsevimab) approved in EU
1st Nov 20223:00 pmRNSTotal Voting Rights
26th Oct 20227:00 amRNSCapivasertib Phase III trial met primary endpoints
25th Oct 20227:00 amRNSUpdate on MESSINA Phase III trial
24th Oct 20227:00 amRNSImfinzi + Imjudo approved in advanced liver cancer
3rd Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202210:30 amRNSBoard Committee Changes
27th Sep 20227:05 amRNSKoselugo approved in Japan for NF1
27th Sep 20227:00 amRNSTezspire approved in Japan for severe asthma
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
22nd Sep 20227:00 amRNSLynparza approved in China for ovarian cancer
21st Sep 20227:00 amRNSTezspire approved in the EU for severe asthma
20th Sep 20227:00 amRNSEvusheld approved in EU for COVID-19 treatment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Track Your Investments

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.